T-ChOS

T-ChOS is a specific mixture of three chitosan oligosaccharides (COS) that was investigated as a dietary supplement for the adjuvant treatment of surgically resected pancreatic adenocarcinoma. Chitosan oligosaccharides are low-molecular-weight, water-soluble polymers derived from the deacetylation and hydrolysis of chitin, typically sourced from crustacean shells. They are hypothesized to possess anti-tumor properties, including the ability to induce apoptosis in malignant cells, inhibit angiogenesis, and modulate the host immune response. In a Phase 2 clinical trial (NCT02139202) conducted by Herlev Hospital, T-ChOS was evaluated in combination with standard adjuvant chemotherapy (gemcitabine and capecitabine) to determine its impact on survival outcomes. However, the trial was terminated early due to slow patient recruitment.

Other names

Triple-Chitosan OligosaccharideChitosan oligosaccharideCOS